Bempedoic acid is a non-statin lipid-lowering medication used to reduce LDL cholesterol when statins alone aren’t enough or when statins aren’t tolerated.
Key points
- What it is: An oral drug that lowers LDL-C by inhibiting ATP citrate lyase (ACLY) in the liver. It’s a prodrug activated in the liver and has little effect in skeletal muscle, which can be relevant for people with statin-associated muscle symptoms.
- Brand options and combos:
- Nexletol: bempedoic acid 180 mg once daily (monotherapy or with other non-statin therapies).
- Nexlizet: bempedoic acid 180 mg plus ezetimibe 10 mg once daily (combination therapy).
- Indications:
- Adults with atherosclerotic cardiovascular disease (ASCVD) or heterozygous familial hypercholesterolemia (HeFH) who need additional lowering of LDL-C on maximally tolerated statin therapy, or in patients who are statin-intolerant.
- How well it works (rough idea):
- LDL-C reductions typically in the 15–25% range when added to statins; larger reductions when combined with ezetimibe (as in Nexlizet). Individual response varies.
- Dosing:
- Nexletol: 180 mg once daily.
- Nexlizet: 180 mg bempedoic acid + 10 mg ezetimibe once daily.
- If taken with a statin, there may be considerations to limit certain statin doses to reduce risk of muscle-related side effects (see below).
- Important safety and monitoring:
- Common adverse effects: upper respiratory infections, back pain, headaches, diarrhea, nausea; increased uric acid (hyperuricemia) which can lead to gout.
- Serious but less common: tendon rupture (rare), hypersensitivity reactions, elevations in liver enzymes.
- Liver disease: not recommended in active liver disease; use caution in mild to moderate hepatic impairment.
- Gout risk: monitor uric acid levels and signs of gout, especially in patients with a history of gout.
- Interactions and usage tips:
- Statins: coadministration can increase statin exposure and risk of myopathy. If used with simvastatin, limit the dose to 20 mg/day; with pravastatin, limit to 40 mg/day (higher doses may raise myopathy risk). Other statins should be used with caution; your clinician may choose a statin dose that minimizes risk.
- With ezetimibe (Nexlizet), no major additional interactions beyond what would be expected with ezetimibe.
- Dosing considerations and precautions:
- Not a replacement for statins when statins are indicated; rather, an add-on or alternative if statins aren’t tolerated or need additional LDL-C lowering.
- Pregnancy and breastfeeding: avoid during pregnancy; discuss family planning with your clinician.
- How to monitor:
- Check LDL-C response after 4–12 weeks of therapy.
- Periodic liver function tests and uric acid levels (especially if you have a history of gout or liver disease).
- Watch for signs of muscle pain, weakness, or unusual tiredness (even though risk is lower than with some other drugs, report any symptoms).
If you want, tell me:
- Are you already on a statin, ezetimibe, or other lipid-lowering therapy?
- What’s your target LDL-C, and do you have a history of gout or liver disease?
- Do you prefer a single-agent (Nexletol) or combination (Nexlizet) option?
I can tailor a concise summary, dosing plan, and safety notes to your situation.